Pharmaceuticals, Biotechnology and Life Sciences
Tumor regressions demonstrate potential for DPX-Survivac immunotherapy in hard-to-treat solid tumors Data correlations of survivin specific T cell levels and…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative…
Data show the potential of using neoantigens identified from an individual’s tumor to elicit an immune response to cancer mutations…
WASHINGTON–(BUSINESS WIRE)–Today, the Biotechnology Institute announced the winner of the Mentor of the Year Award, who will be recognized next…
INT230-6 well tolerated at all doses given Durable clinical benefit seen in multiple patients Increases in circulating and intratumoral CD4…
In exploratory analysis of ARIEL3 data, Rubraca significantly improved clinically meaningful endpoints including chemotherapy free interval and PFS on next…
Longest Follow-Up Data for KEYTRUDA in Lung Cancer to Date Showed Five-Year Overall Survival Rate of 23.2% with KEYTRUDA in…
New Clinical Data Presented at the 2019 American Society of Clinical Oncology (ASCO) in Chicago, IL DUBLIN & BURLINGAME, Calif.–(BUSINESS…
Evaluation based upon market impact, plus vision and capability Medidata positioned as top company for impact created in market, which…
Phase 3 results featured in oral presentation at ASCO 2019, selected for Best of ASCO 2019 Meetings, and simultaneously published…